Demethylating Agents in the Treatment of Cancer
AbstractGene silencing resulting from aberrant DNA methylation can lead to tumorigenesis. Therefore, drugs that inhibit or interfere with DNA methylation have been used to reactivate and induce silenced gene re-expression in malignancies. Two demethylating agents, azacitidine and decitabine, are approved for the treatment of myelodysplastic syndromes (MDS) by the U.S. Food and Drug Administration (FDA), and are now considered the standard of care in MDS. In this review, we discuss clinical data, including clinical benefits and toxicities, which led to the approval of azacitidine and decitabine. We also summarize findings from clinical trials that used these two demethylating agents in the treatment of solid tumors. Lastly, we discuss some limitations in the use of azacitidine and decitabine in cancer therapy. View Full-Text
Correction (PDF, 19 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Howell, P.M., Jr.; Liu, Z.; Khong, H.T. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals 2010, 3, 2022-2044.
Howell PM, Jr, Liu Z, Khong HT. Demethylating Agents in the Treatment of Cancer. Pharmaceuticals. 2010; 3(7):2022-2044.Chicago/Turabian Style
Howell, Paul M., Jr.; Liu, Zixing; Khong, Hung T. 2010. "Demethylating Agents in the Treatment of Cancer." Pharmaceuticals 3, no. 7: 2022-2044.